Regulatory Milestone Leverage Soleno’s recent FDA approval of the first therapy for hyperphagia in Prader-Willi syndrome as a proof point to accelerate partnerships with specialty pharmacies, payer networks, and patient support organizations seeking approved treatments for rare diseases.

Rare Disease Focus Target institutions, clinics, and patient advocacy groups focused on Prader-Willi syndrome and rare metabolic disorders for co-marketing, clinical education programs, and investigator-initiated studies to expand adoption and access.

Market Risk Signals Monitor ongoing securities litigation and fiduciary duty investigations as indicators of potential reputational risk; pose risk-adjusted engagement strategies and compliance-ready materials when approaching investors or partner organizations.

Financial Scale With substantial revenue and funding, explore strategic collaborations for manufacturing scale, global distribution, and supply chain optimization to support broader market access and ensure consistent hyperphagia therapy supply.

Tech Enablement Position Soleno’s data and technology stack (cloud, data analytics, and safety tracking) to support real-world evidence studies, pharmacovigilance partnerships, and outcome-based pricing discussions with payers and healthcare systems.